Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from boosted protease inhibitors to raltegravir and vascular function in suppressed HIV infection
NL-OMON39957Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir, lopinavir + ritonavir and atazanavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Change in flow-mediated dilatation of the brachial artery. Started Feb 2012; status: active, not recruiting.
02
Drugs
raltegravirlopinavir + ritonaviratazanavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON39957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39957.